Saruparib recapitulates PARP-BRCA synthetic lethality with PARP1-trapping properties limiting its cytotoxicity
Year: 2026
Type: preprint
Abstract: The original concept of PARP synthetic lethality proposes that loss of poly(ADP-ribose) polymerase (PARP) activity selectively kills homologous recombination (HR)-deficient cells. However, clinically approved PARP1/2 inhibitors (PARPis) are used at exposures exceeding those required for catalytic inhibition. At these doses, PARP trapping is cytotoxic to HR-proficient cells and limits the therapeutic window in HR-deficient cancers. Saruparib has been developed as a PARP1-selective inhibitor to reduce PARP2-associated toxicity; yet its PARP1-trapping properties remain incompletely characterized. Here, we show that saruparib exhibits trapping properties distinct from those of conventional PARPis. It causes minimal cytotoxicity in HR-proficient cells and remains minimally toxic in XRCC1-deficient cells, which are highly sensitive to trapping-associated cytotoxicity induced by conventional PARPis. Although methyl methanesulfonate, which induces extensive base damage, increases saruparib-induced PARP1 trapping and cytotoxicity, the overall trapping-associated cytotoxic response is weaker than that induced by olaparib and shows little further dose-dependent increase once catalytic PARP1 inhibition is achieved. Biochemical measurements demonstrated that PARP1-DNA complexes formed in the presence of saruparib are less stable than those in the presence of olaparib or talazoparib. Notably, saruparib potently kills BRCA1-, BRCA2-, and PALB2-deficient cells at concentrations sufficient for near-maximal catalytic inhibition, without a corresponding increase in cytotoxicity in HR-proficient cells. Thus, saruparib combines potent HR-deficient-selective cytotoxicity with limited PARP1 trapping and associated toxicity. Consequently, saruparib closely recapitulates the PARP-BRCA synthetic lethality while sparing HR-proficient cells, providing a mechanistic framework for its rational clinical use.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236564569
